The antidepressant paroxetine (Paxil) was found in one study to decrease methampetamine craving compared to placebo.

The National Institute of Drug Abuse (NIDA) has recently established the Methamphetamine Clinical Trials Group (MCTG) to conduct studies of medications for methamphetamine. The first MCTG protocol is examining use patterns of methamphetamine and the withdrawal syndrome, followed by studies of the compound ondansetron. Ondansetron, an anti-nausea drug, blocks a specific type of binding site for the neurotransmitter, serotonin. Human laboratory studies have indicated that ondansetron can block the effects of methamphetamine. In addition to ondansteron, NIDA has about a dozen other compounds that are being studied as possible medications for treating various aspects of methamphetamine addiction.